Natarajan Muthusamy

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. pmc Recombination activation gene-2-deficient blastocyst complementation analysis reveals an essential role for nuclear factor I-A transcription factor in T-cell activation
    Natarajan Muthusamy
    Division of Hematology, Department of Internal Medicine, The OSU Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Int Immunol 23:385-90. 2011
  2. pmc Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate
    Natarajan Muthusamy
    Division of Hematology, The OSU Comprehensive Cancer Center, The Ohio State University, Columbus, USA
    Cancer Genet 204:77-83. 2011
  3. doi request reprint Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia
    Yan Jin
    NSF Nanoscale Science and Engineering Center, Division of Pharmaceutics, College of Pharmacy, Department of Chemical and Biomolecular Engineering, The Comprehensive Cancer Center, and Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
    Mol Pharm 7:196-206. 2010
  4. doi request reprint Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing
    Chee Guan Koh
    Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH 43210, USA
    J Control Release 141:62-9. 2010
  5. pmc Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
    Rosa Lapalombella
    Division of Hematology Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, USA
    Blood 112:5180-9. 2008
  6. pmc The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia
    Rosa Lapalombella
    Department of Medicine, Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Br J Haematol 144:848-55. 2009
  7. pmc FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death
    Lapo Alinari
    Division of Hematology, Department of Medicine, College of Medicine, The Ohio State University, Columbus, USA
    Blood 118:6893-903. 2011
  8. ncbi request reprint FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma
    Qing Liu
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 16:3182-92. 2010
  9. pmc CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody
    Farrukh T Awan
    Division of Hematology Oncology, Department of Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
    Blood 115:1204-13. 2010
  10. pmc Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia
    Bo Yu
    Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA
    Blood 121:136-47. 2013

Collaborators

Detail Information

Publications52

  1. pmc Recombination activation gene-2-deficient blastocyst complementation analysis reveals an essential role for nuclear factor I-A transcription factor in T-cell activation
    Natarajan Muthusamy
    Division of Hematology, Department of Internal Medicine, The OSU Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Int Immunol 23:385-90. 2011
    ..These studies demonstrate for the first time a requirement for the NFI-A transcription factor in antigen receptor-induced T-cell activation events...
  2. pmc Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate
    Natarajan Muthusamy
    Division of Hematology, The OSU Comprehensive Cancer Center, The Ohio State University, Columbus, USA
    Cancer Genet 204:77-83. 2011
    ..These studies provide evidence for potential use of GNKG168 in combination with PWM and PMA in karyotypic analysis of CLL patient samples to better identify chromosomal abnormalities for risk stratification...
  3. doi request reprint Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia
    Yan Jin
    NSF Nanoscale Science and Engineering Center, Division of Pharmaceutics, College of Pharmacy, Department of Chemical and Biomolecular Engineering, The Comprehensive Cancer Center, and Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
    Mol Pharm 7:196-206. 2010
    ..69 nM to 9.05 nM. This study suggests that the combination of pH sensitive LP formulation and Tf mediated targeting is a promising strategy for antisense ODN delivery in leukemia therapy...
  4. doi request reprint Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing
    Chee Guan Koh
    Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH 43210, USA
    J Control Release 141:62-9. 2010
    ..MF LP nanoparticles had higher level of Bcl-2 antisense uptake and showed more efficient down-regulation of Bcl-2 protein level than BM LP nanoparticles...
  5. pmc Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
    Rosa Lapalombella
    Division of Hematology Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, USA
    Blood 112:5180-9. 2008
    ..In addition, they suggest that lenalidomide therapy might be useful to enhance targeted delivery of RNAi-based therapies using CD20 immunoliposomes in B-cell malignancies...
  6. pmc The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia
    Rosa Lapalombella
    Department of Medicine, Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Br J Haematol 144:848-55. 2009
    ..These data together provide justification for clinical trials of SGN-40 and lenalidomide in combination for CLL therapy...
  7. pmc FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death
    Lapo Alinari
    Division of Hematology, Department of Medicine, College of Medicine, The Ohio State University, Columbus, USA
    Blood 118:6893-903. 2011
    ..Significant in vivo therapeutic activity of combination treatment was also demonstrated in a preclinical, in vivo model of MCL. These findings support clinical evaluation of this combination in patients with MCL...
  8. ncbi request reprint FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma
    Qing Liu
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 16:3182-92. 2010
    ..Because of the absence of curative therapy for MCL, we explored FTY720 as a novel agent against MCL...
  9. pmc CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody
    Farrukh T Awan
    Division of Hematology Oncology, Department of Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
    Blood 115:1204-13. 2010
    ..These findings provide strong support for further clinical development of XmAb5574 as both a monotherapy and in combination with lenalidomide for the therapy of CLL and related CD19(+) B-cell malignancies...
  10. pmc Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia
    Bo Yu
    Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA
    Blood 121:136-47. 2013
    ..The broader implications of similar approaches in overcoming immunostimulatory properties of RNA-directed therapeutics in hematologic malignancies are also discussed...
  11. doi request reprint A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents
    Rosa Lapalombella
    Division of Hematology Oncology, Department of Internal Medicine, Ohio State University, Columbus, OH 43210, USA
    Clin Cancer Res 14:569-78. 2008
    ..We describe generation and utilization of cell lines that stably express CD52 both in vitro and in vivo...
  12. pmc Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway
    Rosa Lapalombella
    Division of Hematology and Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
    Blood 115:2619-29. 2010
    ..This study is registered at http://clinicaltrials.gov as NCT00466895...
  13. pmc Differential effects of IL-2 and IL-21 on expansion of the CD4+ CD25+ Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia
    Aruna Gowda
    Division of Hematology and Oncology, Department of Internal Medicine, Seattle, WA, USA
    MAbs 2:35-41. 2010
    ..Given the infusion related toxicities and pro-survival effect of IL-2 in CLL, these studies provide a rationale to explore IL-21 as an alternate gamma chain cytokine in CLL therapy...
  14. pmc Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells
    Bo Yu
    Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA
    Biomaterials 34:6185-93. 2013
    ..Our findings suggest that the dual-ligand ILs may provide a preferred strategy of personalized nanomedicine for the treatment of B-cell malignancies...
  15. pmc Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia
    Xiaomeng Huang
    Molecular, Cellular and Developmental Biology, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 19:2355-67. 2013
    ..To overcome these limitations, we developed a novel transferrin-conjugated nanoparticle delivery system for synthetic miR-29b (Tf-NP-miR-29b)...
  16. pmc Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties
    Sarwish Rafiq
    Integrated Biomedical Science Graduate Program, The Ohio State University, Columbus, OH 43210, USA
    J Immunol 190:2702-11. 2013
    ..These findings bear relevance to potential combination strategies with each of these anti-CD20 Abs in the treatment of CLL...
  17. pmc Synthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivity
    Hongyan Wang
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
    Mol Pharm 9:1638-44. 2012
    ..This study supports future exploration of miR-involved combination therapies...
  18. pmc FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma
    Qing Liu
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA
    Blood 111:275-84. 2008
    ..These results provide the first evidence for the potential use of FTY720 as a therapeutic agent in a variety of B-cell malignancies, including CLL...
  19. ncbi request reprint Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro
    Sabyasachi Biswas
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Leuk Res 34:925-31. 2010
    ..Furthermore, Hu1D10-mediated cell death was enhanced with ATO and ascorbic acid, thus justifying potential combination of ATO/arsenic trioxide therapy with antibodies such as Hu1D10 that also cause accumulation of ROS...
  20. pmc Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma
    Lapo Alinari
    Division of Hematology, Department of Medicine, College of Medicine, The Ohio State University, Columbus, USA
    Blood 117:4530-41. 2011
    ..Significant in vivo therapeutic activity of combination rituximab and milatuzumab was demonstrated in a preclinical model of MCL. These data support clinical evaluation of combination milatuzumab and rituximab therapy in MCL...
  21. pmc Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals
    Rosa Lapalombella
    Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Cancer Cell 21:694-708. 2012
    ....
  22. pmc Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy
    Jonathan P Butchar
    Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
    Clin Cancer Res 16:2065-75. 2010
    ..Here, we wished to test the effect of TLR7/8 activation on monocyte Fcgamma receptor (FcgammaR) function, as they are critical mediators of antibody therapy...
  23. pmc Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma
    Hany A Omar
    Division of Medicinal Chemistry, College of Pharmacy, Ohio State University, Columbus, OH 43210, USA
    Hepatology 53:1943-58. 2011
    ..Finally, OSU-2S exhibited high in vivo potency in suppressing xenograft tumor growth in both ectopic and orthotopic models without overt toxicity...
  24. pmc The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia
    Sarah E M Herman
    Integrated Biomedical Science Graduate Program, The Ohio State University Medical Center, Columbus, OH 43210, USA
    Blood 117:4323-7. 2011
    ....
  25. pmc Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells
    Erin Hertlein
    Department of Internal Medicine, Division of Hematology, The Comprehensive Cancer Center at The Ohio State University, Columbus, OH 43210, USA
    Blood 116:2554-8. 2010
    ..Based on these data, future development of the milatuzumab-immunoliposome formulation as a therapeutic agent for CLL is warranted...
  26. pmc IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro
    Aruna Gowda
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, USA
    Blood 111:4723-30. 2008
    ....
  27. ncbi request reprint Activation induced differential regulation of stem cell antigen-1 (Ly-6A/E) expression in murine B cells
    Hui Chen Chen
    Department of Pediatrics, Center for Human and Molecular Genetics, Columbus Children s Research Institute, The Ohio State University, Columbus, OH 43205, USA
    Cell Immunol 225:42-52. 2003
    ..These studies provide the first evidence for activation induced differential modulation and differentiation of Ly-6A/E(+) B cells...
  28. pmc Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma
    Qing Liu
    Division of Pharmaceutics, College of Pharmacy, Comprehensive Cancer Center, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210, USA
    Ther Drug Monit 30:620-7. 2008
    ..This sensitivity will enable late terminal phase concentration measurements and accurate pharmacokinetic parameter estimation in a planned clinical trial with lenalidomide and flavopiridol in patients with chronic lymphocytic leukemia...
  29. pmc Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies
    Yicheng Mao
    Division of Hematology, The Comprehensive Cancer Center, Division of Pharmaceutics and Medicinal Chemistry, College of Pharmacy, Ohio State University, Columbus, OH 43210, USA
    Clin Cancer Res 19:347-56. 2013
    ..Herein, we developed novel milatuzumab-conjugated liposomes as a targeted dexamethasone carrier for therapeutic delivery in CD74(+) B-cell malignancies and explored its effect against the disease...
  30. pmc The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma
    Trupti Joshi
    The Ohio State University Biochemistry Program, The Ohio State University, Columbus, Ohio, USA
    PLoS ONE 4:e4208. 2009
    ..Taken together, these findings illustrate that the PtdIns 3-kinase/Akt pathway plays a critical role in macrophage ADCC through its influence on conjugate formation between macrophages and antibody-coated tumor cells...
  31. ncbi request reprint Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment
    Xiaobin Zhao
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    J Pharm Sci 97:1508-18. 2008
    ..These data suggest that adopting liposomes containing coencapsulated drug combinations constitutes a potential strategy to promote drug synergism and may have utility in the treatment of leukemia and lymphoma...
  32. ncbi request reprint Differential role for cyclic AMP response element binding protein-1 in multiple stages of B cell development, differentiation, and survival
    Hui Chen Chen
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, 43210, USA
    J Immunol 176:2208-18. 2006
    ..These studies provide the first evidence for a differential role for CRE-binding proteins in multiple stages of B cell development, functional maturation, and B1 and B2 B cells...
  33. ncbi request reprint Disruption of ZAS3 in mice alters NF-kappaB and AP-1 DNA binding and T-cell development
    Carl E Allen
    Department of Pediatrics and Center for Cell and Developmental Biology, Columbus Children s Research Institute, Columbus, OH 43205, USA
    Gene Expr 14:83-100. 2007
    ..In CD3+ ZAS3-/- thymocytes, the CD4/ CD8 ratio was decreased and CD69 expression was decreased. In peripheral CD4+ ZAS3-/- lymphocytes we observed an increased number of memory T cells...
  34. doi request reprint FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling
    Jui Hsiang Hung
    Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 68:1204-12. 2008
    ..Together, this study provides a rationale to use FTY720 as a scaffold to develop potent PKC delta-activating agents for HCC therapy...
  35. pmc The clinical application of monoclonal antibodies in chronic lymphocytic leukemia
    Samantha M Jaglowski
    Division of Hematology Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
    Blood 116:3705-14. 2010
    ..In addition, recent efforts to combine currently applied therapeutic antibodies with other biologic and targeted therapies with efficacy in CLL offers the potential to move toward alternative non-chemotherapy-based treatment approaches...
  36. pmc Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2
    Xiaojuan Yang
    Division of Pharmaceutics, The Ohio State University, Columbus, Ohio 43210, USA
    Mol Pharm 6:221-30. 2009
    ..Tf-LN-mediated delivery combined with TfR up-regulation by deferoxamine appears to be a potentially promising strategy for enhancing the delivery efficiency and therapeutic efficacy of antisense oligonucleotides...
  37. pmc MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
    Ramiro Garzon
    Department of Medicine, Ohio State University, Columbus, 43210, USA
    Blood 113:6411-8. 2009
    ....
  38. ncbi request reprint A novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery
    Yicheng Mao
    Center for Affordable Nanoengineering of Polymeric Biomedical Devices CANPBD, The Ohio State University, Columbus, OH, USA Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA
    Nanomedicine 10:393-400. 2014
    ....
  39. pmc Role for Ets-2(Thr-72) transcription factor in stage-specific thymocyte development and survival
    Ian B Fisher
    Molecular Cellular Developmental Biology Program, Division of Hematology, Ohio State University, Columbus, Ohio 43210, USA
    J Biol Chem 287:5199-210. 2012
    ..The observed defects in these mice are not dependent on Ets-1 expression. These studies implicate for the first time a stage-specific Ets-1-independent regulatory role for Ets-2 in early thymocyte development and survival...
  40. pmc A novel ultrasensitive hybridization-based ELISA method for 2-methoxyphosphorothiolate microRNAs and its in vitro and in vivo application
    Kenneth K Chan
    The Ohio State University, Columbus, 43210, USA
    AAPS J 12:556-68. 2010
    ..These concentrations are in a range that shows biological activities. We conclude that this method provides a general and valuable tool for the pharmacologic study and clinical development of synthetic miRNAs...
  41. pmc FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia
    Paolo Neviani
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio, USA
    J Clin Invest 117:2408-21. 2007
    ..Altogether, these results highlight the therapeutic relevance of rescuing PP2A tumor suppressor activity in Ph1 leukemias and strongly support the introduction of the PP2A activator FTY720 in the treatment of CML-BC and Ph1 ALL patients...
  42. pmc Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
    Jason A Dubovsky
    Department of Internal Medicine, Division of Hematology
    Blood 122:2539-49. 2013
    ..This trial was registered at www.clinicaltrials.gov as #NCT01105247 and #NCT01217749. ..
  43. pmc Meeting report: The 13th Annual Meeting of the Translational Research Cancer Centers Consortium (TrC3); Immune Suppression and the Tumor Microenvironment, Columbus, Ohio; March 1-2, 2010
    Gregory B Lesinski
    Department of Internal Medicine, The Ohio State University, Arthur G James Cancer Hospital, Richard J Solove Research Institute, Columbus, USA
    J Immunother 33:659-62. 2010
    ..The proceedings of this year's meeting are summarized in this report...
  44. pmc Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis
    Guo Wei
    Department of Molecular and Cellular Biochemistry, The OhioState University, Columbus, OH 43210, USA
    Blood 114:1123-30. 2009
    ..These results establish essential and overlapping functions for Ets1 and Ets2 in coordinating endothelial cell functions with survival during embryonic angiogenesis...
  45. doi request reprint Detection of extracellular RNAs in cancer and viral infection via tethered cationic lipoplex nanoparticles containing molecular beacons
    Yun Wu
    Center for Affordable Nanoengineering of Polymeric Biomedical Devices, The Ohio State University, 174 West 18th Avenue, Room 1012, Columbus, Ohio 43212, United States
    Anal Chem 85:11265-74. 2013
    ..g., quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Here we demonstrate this concept using lentivirus and serum from lung cancer patients. ..
  46. pmc Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis
    Rene Opavsky
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, College of Medicine and Public Health, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 104:15400-5. 2007
    ..These results identify the E2f2 locus as a tumor suppressor through its ability to modulate apoptosis...
  47. pmc Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia
    Amy J Johnson
    Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 108:1334-8. 2006
    ....
  48. ncbi request reprint IFN-gamma-mediated inhibition of antigen receptor-induced B cell proliferation and CREB-1 binding activity requires STAT-1 transcription factor
    Frank Frissora
    Children s Research Institute, Wexner Institute for Pediatric Research, Columbus, OH 43205, USA
    Eur J Immunol 33:907-12. 2003
    ..These studies provide the first evidence for cross-talk between the STAT-1 and CREB-1 signaling pathways in IFN-gamma-mediated negative regulation of B cell activation...
  49. pmc Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing
    Jason A Dubovsky
    Division of Hematology, Department of Internal Medicine
    Blood 122:3308-16. 2013
    ..In addition, we identify LCP1 as a membrane-associated target in CLL with confirmed pathogenic significance. This clinical trial was registered at clinicaltrials.gov; study ID number: OSU-0025 OSU-0156. ..
  50. doi request reprint A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders
    John M Timmerman
    Division of Hematology and Oncology, University of California Los Angeles Medical Center, Los Angeles, California 90095 1678, USA
    Clin Cancer Res 18:5752-60. 2012
    ..We conducted a phase I study to determine the safety, maximum-tolerated dose (MTD), and efficacy of weekly bolus recombinant human interleukin-21 (rIL-21) plus rituximab in patients with indolent B-cell malignancies...
  51. pmc Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical
    Xiaobin Zhao
    Division of Hematology Oncology, Department of Medicine, College of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 110:2569-77. 2007
    ..These findings provide strong justification for CD37 as a therapeutic target and introduce small modular immunopharmaceuticals as a novel class of targeted therapies for B-cell malignancies...
  52. ncbi request reprint Cholesterol as a bilayer anchor for PEGylation and targeting ligand in folate-receptor-targeted liposomes
    Xiaobin B Zhao
    Division of Pharmaceutics, NCI OSU Comprehensive Cancer Center, NSF Nanoscales Science and Engineering Center NSEC, College of Pharmacy, The Ohio State University, 542 LM Parks Hall, 500 W 12th Ave, Columbus, Ohio 43210, USA
    J Pharm Sci 96:2424-35. 2007
    ..In addition, in vivo circulation of cholesterol-anchored liposomes was prolonged compared to non-PEGylated liposomes. These studies suggest that cholesterol is a viable bilayer anchor for synthesis of PEGylated and FR-targeted liposomes...